(S)-2-氨基丁酸甲酯 | 15399-22-1

• 物质功能分类: 分析化学 - 标准品 - 药典标准品和杂质标准品
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: (S)-2-氨基丁酸甲酯
• 中文别名: L-2-氨基丁酸甲酯盐酸盐；左乙拉西坦杂质19
• 英文名称: methyl (S)-2-aminobutanoate
• 英文别名: (S)-2-aminobutyric acid methyl ester；(S)-methyl 2-aminobutanoate；methyl (2S)-2-aminobutanoate
• CAS: 15399-22-1
• 化学式: C₅H₁₁NO₂
• 分子量: 117.148
• InChiKey: ZZWPOYPWQTUZDY-BYPYZUCNSA-N

物化性质

• 沸点：
  127.8±13.0 °C(Predicted)
• 密度：
  0.987±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  8
• 可旋转键数：
  3
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  52.3
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Methyl (2s)-2-aminobutanoate
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Methyl (2s)-2-aminobutanoate
CAS number: 15399-22-1

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C5H11NO2
Molecular weight: 117.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  (S)-2-氨基丁酸甲酯 在 氨 、 盐酸 作用下， 以 异丙醇 为溶剂， 反应 37.0h， 以92.8%的产率得到(S)-(+)-2-氨基丁酰胺盐酸盐
  参考文献：
  名称：

  一种左乙拉西坦关键中间体(S)-2-氨基丁酰 胺盐的制备方法

  摘要：

  本发明公开了一种左乙拉西坦关键中间体(S)‑2‑氨基丁酰胺盐的制备方法，属于药物中间体合成技术领域。本发明的制备方法是将化合物1在C1～C3烷基醇中发生氨解反应，反应完毕后减压浓缩至干，加入醇类溶剂进一步通入氨气游离，过滤浓缩后加入醇类溶剂溶清，滴加酸的醇类溶剂成盐后养晶，制备纯化得到化合物2，其中X为盐酸、氢溴酸或甲磺酸。本发明所述的制备方法简便有效，收率和纯度大大提高，其中摩尔收率大于90％，纯度大于99.5％，为后续左乙拉西坦的制备提供了高质量的中间体，该制备方法没有手性拆分的步骤，溶剂单一，回收简单，三废较少，符合工业化生产的要求。

  公开号：

  CN107673984B
• 作为产物：
  描述：

  L-蛋氨酸甲酯盐酸盐 在 Raney nickel 作用下， 以 水 为溶剂， 反应 4.0h， 以64%的产率得到(S)-2-氨基丁酸甲酯
  参考文献：
  名称：

  用于合成抗癫痫和抗结核活性药物成分的对映体纯中间体的连续流方案

  摘要：

  手性中间体的连续流生产在活性药物成分（API）的基础材料的开发中起着重要作用，因为α-氨基酸及其衍生物被广泛用作基础材料。在这项工作中，我们开发了两种用于合成左乙拉西坦/溴乙酰胺和乙胺丁醇的中间体的合成策略。获得的结果表明，通过RANEY®镍脱硫/还原策略，蛋氨酸甲酯可连续转化为所需的乙胺丁醇中间体，而RANEY®镍（无H 2）和Pd / C–H 2均可合成左乙拉西坦/溴乙酰胺中间体。途径或通过光化学脱硫。

  DOI：

  10.1039/c8ob03088j

文献信息

• Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors
  作者：Shuai Liu、Hailemichael O. Yosief、Lingling Dai、He Huang、Gagan Dhawan、Xiaofeng Zhang、Alex M. Muthengi、Justin Roberts、Dennis L. Buckley、Jennifer A. Perry、Lei Wu、James E. Bradner、Jun Qi、Wei Zhang

  DOI：10.1021/acs.jmedchem.8b00765

  日期：2018.9.13

  inhibition of polo-like kinase 1 (PLK1) and BRD4 bromodomain by a single molecule could lead to the development of an effective therapeutic strategy for a variety of diseases in which PLK1 and BRD4 are implicated. Compound 23 has been found to be a potent dual kinase-bromodomain inhibitor (BRD4-BD1 IC50 = 28 nM, PLK1 IC50 = 40 nM). Compound 6 was found to be the most selective PLK1 inhibitor over BRD4

  通过单个分子同时抑制 Polo 样激酶 1 (PLK1) 和 BRD4 溴结构域可能会导致开发出针对 PLK1 和 BRD4 涉及的多种疾病的有效治疗策略。化合物 23 被发现是一种有效的双激酶-溴结构域抑制剂（BRD4-BD1 IC50 = 28 nM，PLK1 IC50 = 40 nM）。发现化合物 6 是我们系列中相对于 BRD4 最具选择性的 PLK1 抑制剂（BRD4-BD1 IC50 = 2579 nM，PLK1 IC50 = 9.9 nM）。 23 和 BRD4-BD1/PLK1 以及 6 的分子对接研究证实了生化测定结果。
• DIHYDROPTERIDINONE DERIVATIVES, PREPARATION PROCESS AND PHARMACEUTICAL USE THEREOF
  申请人：Tang Peng Cho

  公开号：US20120184543A1

  公开（公告）日：2012-07-19

  Dihydroperidinone derivatives, preparation process and pharmaceutical use thereof are disclosed. Specially, new dihydroperidinone derivatives represented by general formula (I), wherein each substituent of the general formula (I) is defined as in the description, their preparation process, pharmaceutical compositions comprising said derivatives and their use as therapeutical agents, especially as Plk kinase inhibitors are disclosed.

  二氢吡啶酮衍生物、其制备方法及药用途被揭示。特别是，根据通用式(I)表示的新二氢吡啶酮衍生物，其中通用式(I)的每个取代基如描述中所定义，它们的制备过程，包含所述衍生物的药物组合物以及它们作为治疗剂的用途，特别是作为Plk激酶抑制剂的用途被揭示。
• Preparation and biological evaluation of soluble tetrapeptide epoxyketone proteasome inhibitors
  作者：Meng Lei、Haoyang Zhang、Hang Miao、Xiao Du、Hui Zhou、Jia Wang、Xueyuan Wang、Huayun Feng、Jingmiao Shi、Zhaogang Liu、Jian Shen、Yongqiang Zhu

  DOI：10.1016/j.bmc.2019.07.044

  日期：2019.9

  in mice, rat and human microsomes than marketed carfilzomib. The in vivo activities of this compound were evaluated with the xenograft mice models of MM cell lines ARH77 and RPMI-8226 with luciferase expression and the T/C value of the two models were 49.5% and 37.6%, respectively. To evaluate the potential cardiovascular toxicity, inhibition of hERG ion channel in HEK293 cells by compound 36 and carfilzomib

  设计并合成了一系列新型的20S蛋白酶体四肽基环氧酮抑制剂。为了充分理解SAR，设计，合成和生物分析了R 1，R 2，R 3，R 4和R 5位置的各种基团，包括芳族和脂族取代基。基于酶促结果，选择了7种化合物来评估其细胞活性，可溶性化合物36对人多发性骨髓瘤（MM）细胞系显示出强大的功效。微粒体稳定性结果表明化合物36与市售的卡非佐米相比，它在小鼠，大鼠和人的微粒体中更稳定。用具有荧光素酶表达的MM细胞系ARH77和RPMI-8226的异种移植小鼠模型评价该化合物的体内活性，两个模型的T / C值分别为49.5％和37.6％。为了评估潜在的心血管毒性，化合物36和卡非佐米对HEK293细胞中的hERG离子通道进行了抑制。结果表明36对hERG离子通道没有结合亲和力，而卡非佐米可以与92.1μM的IC 50结合。
• Synthesis of Novel Chiral Phenanthroline Ligands and a Copper Complex
  作者：Xueyan Yang、Zhipeng Zhang、Jingjing Tang、Jian Li

  DOI：10.1055/a-1679-7161

  日期：2022.11

  A novel class of chiral multidentate ligands has been designed and synthesized from the important classic ligand 1,10-phenanthroline and amino acids. The ligands were proven to be able to coordinate with copper(2+) ion by the formation of a novel chiral copper complex, the structure of which was determined by single-crystal X-ray diffraction.

  从重要的经典配体 1,10-菲咯啉和氨基酸中设计并合成了一类新的手性多齿配体。通过形成新型手性铜配合物，证明配体能够与铜 (2+) 离子配位，其结构由单晶 X 射线衍射确定。
• Application of Sequential Palladium Catalysis for the Discovery of Janus Kinase Inhibitors in the Benzo[<i>c</i>]pyrrolo[2,3-<i>h</i>][1,6]naphthyridin-5-one (BPN) Series
  作者：Mohamed S. A. Elsayed、Jeffery J. Nielsen、Sungtae Park、Jeongho Park、Qingyang Liu、Chang H. Kim、Yves Pommier、Keli Agama、Philip S. Low、Mark Cushman

  DOI：10.1021/acs.jmedchem.8b00510

  日期：2018.12.13

  The present account describes the discovery and development of a new benzo[c]pyrrolo[2,3-h][1,6]naphthyridin-5-one (BPN) JAK inhibitory chemotype that has produced selective JAK inhibitors. Sequential palladium chemistry was optimized for the rapid access to a focused library of derivatives to explore the structure–activity relationships of the new scaffold. Several compounds from the series displayed

  该文献描述了已经产生选择性JAK抑制剂的新型苯并[ c ]吡咯并[2，3- h ] [1，6]萘啶-5-酮（BPN）JAK抑制化学型的发现和开发。优化了顺序钯化学，可快速访问聚焦的衍生物库，以探索新支架的结构与活性之间的关系。该系列中的几种化合物对JAK家族的四个成员具有不同选择性的低纳摩尔浓度范围。具有氮杂环丁烷酰胺侧链的化合物20a显示出对JAK1激酶相对于JAK2，JAK3和TYK2的最佳选择性，且纳摩尔浓度低（IC 50 = 3.4 nM）。另一方面，BPN 17b和18对JAK家族具有良好的总体活性，并具有优异的kinome选择性特征。许多新的BPN抑制JAK3介导的STAT-5磷酸化，炎性细胞因子的产生以及原代T细胞的增殖。此外，在类风湿性关节炎动物模型中，BPN 17b的体内结果与托法替尼非常相似。